


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An oxygen infusion for increasing an oxygen concentration in tumor tissues in living bodies, said oxygen infusion comprising a dispersion of an albumin clathrate compound including porphyrin metal complex, dispersed in a physiologically permissible aqueous media, wherein said porphyrin metal complex is a porphyrin metal complex represented by the general formula (I):

General formula (I)



where R1 is a chain or alicyclic hydrocarbon group that may have one or more substituents, R2 is a basic axial ligand expressed by the formula (A):

wherein R1 is:


a C₁-C₁₉ chain hydrocarbon group having dimethyl groups at the first position; or

a C₃-C₁₉ alicyclic hydrocarbon group having a substituent at the first position,

wherein each substituent is a methyl, C₁-C₁₈ alkylamide, C₁-C₁₈ alkanoyloxy, or C₁-C₁₈ alkoxy;

R2 is a basic axial ligand expressed by the formula (A):


Formula (A)



[[where]] wherein R_3 is ~~alkylene~~, a C_1 - C_{10} alkylene; and

R_4 is ~~a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M, and M is a transition metal ion of the 4th or 5th period of the periodic table of elements.~~ hydrogen, methyl, ethyl, propyl or a basic axial ligand represented by the formula (B):

Formula (B)



wherein R_5 is a C_1 - C_{10} alkylene;

R_6 is a C_1 - C_{18} alkyl; and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

2. (Cancelled)

3. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R_1 is C_3 - C_{19} alicyclic hydrocarbon having a substituent at the first position, R_2 is a basic axial ligand

expressed by the formula (A) where R_3 is C_1 - C_{10} alkylene, R_4 is hydrogen, methyl, ethyl or propyl, and M is Fe or Co.

4. (Cancelled)

5. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R_1 is a C_1 - C_{19} chain hydrocarbon group having dimethyl groups at the first position, R_2 is a basic axial ligand expressed by the formula (A) where R_3 is C_1 - C_{10} alkylene, R_4 is hydrogen, methyl, ethyl or propyl and M is Fe or Co.

6. (Cancelled)


7. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(2-methyl-1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-($\alpha,\alpha,\alpha,\alpha$ -o-pivaloylamidophenyl)porphyrin iron (II) complex.

8. (Previously presented) The oxygen infusion according to claim 1, wherein said porphyrin metal complex is 2-8-(1-imidazolyl)octanoyloxymethyl-5, 10, 15, 20-tetrakis-($\alpha,\alpha,\alpha,\alpha$ -o-(1-methyl cyclohexanoyl) aminophenyl) porphyrin iron (II) complex.

9. (Currently amended) The oxygen infusion according to claim 1, wherein said albumin clathrate compound further includes a porphyrin metal complex represented by the general

formula (II):

General formula (II)




where R₇ is hydrogen or a chain hydrocarbon group ~~that may have~~ optionally having one or more substituents,

R₈ is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue,


R₉ is a basic axial ligand represented by the formula (C):

Formula (C)



where R₁₀ is alkylene, R₁₁ is ~~a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M~~ a hydrogen, methyl, ethyl, propyl or a basic axial ligand represented by the formula (D):

Formula (D)



wherein R₁₂ is an alkyl, and an

M is a transition metal ion of the 4th or 5th period of the periodic table of elements.


10. (Previously presented) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which R₇ is hydrogen, vinyl, ethyl or methoxy, R₈ is C₁-C₁₈ alkyloxy, C₁-C₁₈ alkylamino, an amino acid or a derivative residue of the amino acid, R₁₀ is C₁-C₁₀ alkylene, R₁₁ is hydrogen, methyl, ethyl or propyl, and M is Fe or Co.

11. (Previously presented) The oxygen infusion according to claim 9, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or more substituents are selected from the group consisting of methyl, C₁-C₁₈ alkylamide, C₁-C₁₈ alkanoyloxy and C₁-C₁₈ alkoxy.

12. (Previously presented) The oxygen infusion according to claim 9, wherein said porphyrin metal complex of the general formula (II) is 8,13-bisvinyl-2-methoxycarbonylethyl-18-(3-(1-imidazolyl) propylamino) carbonylethyl-3,7,12,17-tetramethyl porphyrin iron (II) complex.


13. (Previously presented) The oxygen infusion according to claim 1, where said albumin clathrate compound further includes a porphyrin metal complex represented by the general formula (II):

General formula (II)



wherein R_7 is hydrogen or a chain hydrocarbon group that may have one or more substituents, R_8 is alkyloxy, alkylamino, or an amino acid or amino acid derivative residue, R_9 is a basic axial ligand expressed by the formula (D):

Formula (D)



where R_{12} is alkyl, and M is a transition metal ion of the 4th or 5th period of the periodic table of elements.

14. (Previously presented) The oxygen infusion according to claim 13, wherein R₇ is hydrogen, vinyl, ethyl or methoxy, R₈ is C₁-C₁₈ alkyloxy, C₁-C₁₈ alkylamino, amino acid or a derivative residue thereof, R₁₂ is C₁-C₁₈ alkyl, and M is Fe or Co.

15. (Previously presented) The oxygen infusion according to claim 13, wherein said albumin clathrate compound includes a porphyrin metal complex of the general formula (II), in which said one or more substituents are the ones selected from the group consisting of methyl, C₁-C₁₈ alkylamide, C₁-C₁₈ alkanoyloxy and C₁-C₁₈ alkoxy.